Forbes: 11 pharmaceutical companies with strong profit growth

On July 26, Forbes released the list of small and medium-sized listed enterprises in Asia, while 108 enterprises from mainland China, Hong Kong and Taiwan accounted for half of the list The list is to select 200 listed companies in the Asia Pacific region with annual revenue between us $5 million and US $1 billion, which have historically had strong revenue and profit growth According to incomplete statistics of medical observer network, there are 11 Chinese enterprises in the pharmaceutical industry, including Sansheng pharmaceutical, aer Ophthalmology, Puli pharmaceutical, Kangtai biology, Jichuan pharmaceutical, etc It is reported that the sales and earnings per share growth of the listed companies in the last fiscal year and three fiscal years are relatively the highest Moreover, their 1-year and 5-year average equity returns were also the strongest It is worth noting that Kangtai bio, a pharmaceutical enterprise, was also selected Although its stock fell for three consecutive days and its share price fell to the lowest level in three months due to the impact of the unqualified vaccine production by China Changsheng bio But Forbes admits its share price is still three times that of more than a year ago In addition, aer ophthalmology has been listed for the third consecutive year with a market value of 12.3 billion US dollars, the largest market value among the 200 listed companies.